How M.P.H. was paid
$10.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Total |
|---|---|---|---|
| Ryan Saadi, M.D., M.P.H.Chief Executive Officer | $501,000 | $9,920,000 | $10,421,000 |
| Kirti DesaiChief Financial Officer | $300,000 | $930,000 | $1,230,000 |
| Neal Flomenberg, M.D.Chief Scientific Officer and Global R&D Lead | $350,000 | $372,000 | $722,000 |
What changed and why
- $10.4M$10,421,000 was CEO total compensation in 2025, down from $87,764,783 in 2024.
- $9.9M$9,920,000 was the CEO’s 2025 stock award, compared with $87,263,783 in 2024.
- $62.00$62.00 per share was the fair value for the June 2025 restricted stock awards.
- 10%386,979 shares comprised the CEO’s Special RSU Award, representing approximately 10% of common stock fully diluted.
- 2031 was the first scheduled vesting year for the CEO’s Special RSU Award.
- No named executive officer held outstanding stock options at December 31, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.